Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine

por Spierings, Egilius LH, Brandes, Jan Lewis, Kudrow, David B, Weintraub, James, Schmidt, Peter C, Kellerman, Donald J, Tepper, Stewart J
Publicado 2017

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

por Brandes, Jan Lewis, Klise, Suzanne, Krege, John H, Case, Michael, Khanna, Rashna, Vasudeva, Raghavendra, Raskin, Joel, Pearlman, Eric M, Kudrow, David
Publicado 2019

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial

por Tepper, Stewart J., Diener, Hans-Christoph, Ashina, Messoud, Brandes, Jan Lewis, Friedman, Deborah I., Reuter, Uwe, Cheng, Sunfa, Nilsen, Jon, Leonardi, Dean K., Lenz, Robert A., Mikol, Daniel D.
Publicado 2019

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

por Ashina, Messoud, Tepper, Stewart J., Brandes, Jan Lewis, Reuter, Uwe, Boudreau, Guy P., Weatherall, Mark, Gantenbein, Andreas R., Doležil, David, Klatt, Jan, Wang, Andrea, Karanam, Ananda Krishna, Cheng, Sunfa, Mikol, Daniel D.
Publicado 2022